Manufacturing Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing Pharmaceutical TechnologyGlobalData's Drugs By Manufacturer Database reveals the top four CDMOs for innovator and biosimilar HPAPI contract manufacturing.Read full story pharminent July 22, 2026 (Last updated: July 27, 2026) Pharmaceutical Technology GlobalData’s Drugs By Manufacturer Database reveals the top four CDMOs for innovator and biosimilar HPAPI contract manufacturing. Read full story Post navigation Previous: Samsung Biologics: geographic diversification is a sound business decisionNext: Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
